VHL and hypoxia signaling: Beyond HIF in cancer

Jing Zhang, Qing Zhang

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1α and HIF2α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-κB signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer.

Original languageEnglish (US)
Article number35
JournalBiomedicines
Volume6
Issue number1
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Neoplasms
Ubiquitin-Protein Ligases
Kidney Neoplasms
Proteasome Endopeptidase Complex
Crosstalk
Carcinoma
Tumors
Genes
Cells
Degradation
Hypoxia
Substrates

Keywords

  • ccRCC
  • Hypoxia
  • VHL

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

VHL and hypoxia signaling : Beyond HIF in cancer. / Zhang, Jing; Zhang, Qing.

In: Biomedicines, Vol. 6, No. 1, 35, 01.03.2018.

Research output: Contribution to journalReview article

@article{d1b1cffd4d7540018a2cb9b9818f4c08,
title = "VHL and hypoxia signaling: Beyond HIF in cancer",
abstract = "Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1α and HIF2α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-κB signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer.",
keywords = "ccRCC, Hypoxia, VHL",
author = "Jing Zhang and Qing Zhang",
year = "2018",
month = "3",
day = "1",
doi = "10.3390/biomedicines6010035",
language = "English (US)",
volume = "6",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - VHL and hypoxia signaling

T2 - Beyond HIF in cancer

AU - Zhang, Jing

AU - Zhang, Qing

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1α and HIF2α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-κB signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer.

AB - Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1α and HIF2α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-κB signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer.

KW - ccRCC

KW - Hypoxia

KW - VHL

UR - http://www.scopus.com/inward/record.url?scp=85056271743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056271743&partnerID=8YFLogxK

U2 - 10.3390/biomedicines6010035

DO - 10.3390/biomedicines6010035

M3 - Review article

C2 - 29562667

AN - SCOPUS:85056271743

VL - 6

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 1

M1 - 35

ER -